Robenacoxib for Feline Musculoskeletal Pain: COX-2 Selectivity, DJD Evidence, Safety, and the ISFM/AAFP Framework

Bottom line

• Robenacoxib (Onsior) is the only licensed coxib-class NSAID for cats; its COX-2 selectivity (in vitro IC₅₀ COX-1:COX-2 ratio 32:1 in cats) and short blood half-life (<2 h) combined with tissue-selective accumulation in inflamed sites underpin its feline safety profile.¹
• A randomized blinded pilot clinical trial in 109 cats with degenerative joint disease-associated pain (DJD-pain) showed robenacoxib produced a 49% reduction in owner-assessed disability (p = 0.01, effect size ~0.3) and a significantly higher success rate at 6 weeks (p = 0.018, NNT 3.8) compared with placebo.²
• A pooled safety analysis of 4 prospective randomized blinded clinical trials (n = 449 cats with chronic musculoskeletal disease, 4–12 weeks) found the relative risk of at least one adverse event with robenacoxib versus placebo was 1.15 (95% CI 0.93–1.43); in the 126-cat CKD subgroup the relative risk was 1.09 (95% CI 0.78–1.52).³
• The 2024 ISFM/AAFP consensus guidelines on long-term NSAID use in cats identify robenacoxib and meloxicam as the most widely studied NSAIDs in cats, and address use in the presence of comorbidities, particularly chronic kidney disease, with specific monitoring requirements.⁴
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Coxib-class NSAID (selective COX-2 inhibitor); diphenylamine derivative.¹
• COX selectivity: In vitro IC₅₀ COX-1:COX-2 ratio of 32:1 in cats — produces significant inhibition of COX-2 whilst sparing COX-1 at registered dosages.¹
• Pharmacokinetics (cats): Plasma protein binding >98%; terminal blood half-life <2 h; low body clearance (0.44 L/kg/h); biliary excretion predominates (~72% in cats); concentrates in inflamed tissues enabling once-daily dosing despite the short blood half-life.¹
• Licensed dosages (cats): Oral 1–2.4 mg/kg once daily; 2 mg/kg SC once (or up to 2 consecutive days perioperatively) — always confirm dose range and approved treatment duration with current product labeling.¹
• Approved indications in cats (EU/EMA): Acute pain and inflammation associated with musculoskeletal disorders (oral tablets, up to 6 days); perioperative pain (injection); confirm local-market authorization before prescribing for chronic pain beyond the labeled duration.^1,4
• Key species note: Cats have limited glucuronyl transferase capacity, making NSAID selection and dosing interval particularly important; robenacoxib's short blood half-life and biliary excretion pathway partially mitigate, but do not eliminate, NSAID risk in this species.^1,4

A specific patient on robenacoxib or feline DJD pain?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Mechanism: tissue-selective COX-2 inhibition

Robenacoxib belongs to the coxib class and achieves COX-2 selectivity through its diphenylamine chemical scaffold.¹ In feline whole-blood assays, the in vitro IC₅₀ COX-1:COX-2 ratio is 32:1, confirming preferential COX-2 inhibition at therapeutic concentrations.¹ The pharmacokinetic profile is critically important for understanding why this drug has been selected for feline use: its terminal blood half-life is less than 2 hours, which limits systemic COX inhibition duration compared with non-selective NSAIDs with longer half-lives.¹ Despite the short blood half-life, clinical once-daily dosing is effective because robenacoxib selectively distributes to and persists in inflamed tissue, where it continues to exert local COX-2 inhibitory effects even after blood concentrations have fallen.¹ The drug is >98% plasma protein bound and undergoes biliary excretion as the predominant elimination route in cats (~72%), with minimal renal excretion — a pharmacokinetic consideration relevant to use in cats with concurrent renal disease.¹

The safety margin established in preclinical studies is noteworthy: in healthy laboratory cats, daily oral doses 8-fold higher than the recommended clinical dose were well tolerated for 6 weeks.¹ This margin supports confidence in the registered dosage range, while acknowledging that clinical populations with comorbidities require additional monitoring.

Feline DJD pain: the Adrian 2021 pilot RCT

The pivotal clinical evidence base for robenacoxib in feline DJD pain derives from a randomized blinded pilot clinical trial by Adrian et al. (2021) in 109 client-owned cats with degenerative joint disease-associated pain.² The study used a parallel-group, three-arm design (PP, RR, and RP treatment sequence groups, each 3-week period), incorporating both objective actimetry and owner-assessed endpoints.

Key findings: mean total activity was 5.7% higher in robenacoxib-treated cats compared with placebo, and significantly more robenacoxib-treated cats demonstrated a >10% increase in activity at 3 weeks (p = 0.046) and 6 weeks (p = 0.026).² Owner-assessed endpoints showed a 49% reduction in disability score (p = 0.01, effect size ~0.3), along with improved temperament (p = 0.0039) and happiness (p = 0.021) after 6 weeks.² Categorical success rate analysis at 6 weeks favored robenacoxib (p = 0.018, NNT 3.8).² Adverse event frequencies were similar across treatment groups. The authors identified this study's outcomes as suitable endpoints for confirmatory pivotal trials, while noting the objective actimetry data had high within- and between-cat variability (82.4% of values were zero), a recognized challenge in feline pain measurement.

Chronic safety: King 2021 pooled analysis

The most comprehensive safety dataset comes from a pooled analysis of 4 prospective randomized blinded clinical trials by King et al. (2021) — a total of 449 client-owned cats with chronic musculoskeletal disease, receiving robenacoxib (n = 222) or placebo (n = 227) orally once daily for 4 to 12 weeks.³ The number of cats with at least one adverse event was not significantly different between groups (robenacoxib 47.8% vs placebo 41.0%, P = .15), and the relative risk of at least one adverse event was 1.15 (95% CI 0.93–1.43).³

A critical subgroup analysis involved the 126 cats in the dataset with evidence of chronic kidney disease — precisely the comorbidity that most commonly constrains long-term NSAID use in cats. In this subgroup, the relative risk of at least one adverse event with robenacoxib versus placebo was 1.09 (95% CI 0.78–1.52, P = .61), indicating no statistically significant increase in adverse event risk.³ However, the authors noted that serum creatinine concentrations were marginally higher during robenacoxib administration (+4.36 μmol/L, 95% CI 0.21–8.50 μmol/L) without associated adverse clinical effects detected.³ Importantly, the study excluded cats with severe or uncontrolled concomitant diseases, limiting direct generalizability to the most renally compromised patients encountered in general practice.

2024 ISFM/AAFP consensus: framework for long-term NSAID use

The 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats, published in the Journal of Feline Medicine and Surgery, provide the current guideline framework within which robenacoxib decisions should be made.⁴ The guidelines address mechanism of action, indications, screening prior to prescription, use in the presence of comorbidities (particularly CKD, which is common in senior cats), monitoring of efficacy, and management of adverse effects.⁴ Robenacoxib and meloxicam are identified as the most widely studied NSAIDs in cats, with the guidelines supporting their use in chronic pain including in cats with stable, early CKD, provided appropriate monitoring and client communication are in place.⁴ The guidelines explicitly note the cat's unique metabolism (limited glucuronidation) as a relevant consideration when prescribing any NSAID in this species.

How this fits clinical practice

Feline DJD pain — chronic, underdiagnosed, and undertreated — represents a substantial welfare gap in feline medicine. Robenacoxib occupies the central licensed NSAID position for musculoskeletal pain in cats, with a pharmacological rationale (COX-2 selectivity, tissue accumulation, short blood half-life) specifically relevant to feline metabolism, and an evidence base now including a placebo-controlled RCT for DJD-pain and a large pooled safety dataset including a CKD subgroup.

Practical clinical points:

• Pre-treatment baseline renal and hepatic biochemistry is standard practice before initiating NSAIDs in cats; monitoring during long-term treatment is guideline-recommended.
• The licensed duration in many markets (6 days oral) reflects regulatory approval at the time of initial authorization; the evidence base, including the 4–12 week safety trials informing King 2021, extends beyond this. Confirm your local-market authorization before prescribing beyond the label.
• In cats with CKD, the King 2021 CKD subgroup data are reassuring for stable early CKD but cannot be extrapolated to decompensated renal failure; individual risk-benefit assessment and more frequent monitoring are indicated.
• Do not infer specific milligram-per-kilogram doses from this summary; always confirm the exact regimen, interval, and contraindications against current product labeling and a veterinary formulary before prescribing.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ISFM/AAFP consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Lees P, Toutain PL, Elliott J, Giraudel JM, Pelligand L, King JN. 2022. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. J Vet Pharmacol Ther 45(4):325-351. https://europepmc.org/articles/PMC9541287
2. Adrian D, King JN, Parrish RS, et al. 2021. Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial. Sci Rep 11(1):7721. https://europepmc.org/articles/PMC8032665
3. King JN, Seewald W, Forster S, et al. 2021. Clinical safety of robenacoxib in cats with chronic musculoskeletal disease. J Vet Intern Med 35(5):2384-2394. https://europepmc.org/articles/PMC8478032
4. Taylor S, Gruen M, KuKanich K, et al. 2024. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J Feline Med Surg 26(4):1098612X241241951. https://europepmc.org/articles/PMC11103309

Changelog

• 2026-06-23: First published.

---

For licensed veterinary professionals. Evidence summary, not clinical advice. Voyage is decision support, not a substitute for clinical judgment — always confirm dosing and treatment with current formularies and your own clinical judgment.